En undersøgelse af TAR-200 i kombination med Cetrelimab eller TAR-200 alene versus intravesikal Bacillus Calmette-Guérin (BCG) hos deltagere med BCG-naive højrisiko ikke-muskelinvasiv blærekræft (SunRISe-3)
En fase 3, open-label, multicenter, randomiseret undersøgelse, der evaluerer effektiviteten og sikkerheden af TAR-200 i kombination med Cetrelimab eller TAR-200 alene versus intravesikal Bacillus Calmette-Guérin (BCG) hos deltagere med BCG-naive højrisiko Ikke-muskelinvasiv blærekræft
The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS), between TAR-200 plus cetrelimab (Group A) and TAR-200 alone (Group C) versus intravesical BCG (Group B).
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Bladder cancer is the tenth most common malignancy worldwide. About 75 percent (%) of bladder cancers are non-muscle invasive at diagnosis with approximately 25% of NMIBC patients have HR, NMIBC. The TAR-200/gemcitabine (JNJ-17000139) product is an intravesical drug delivery system regulated as an investigational drug. The drug constituent consists of gemcitabine and osmotic minitablets. Cetrelimab (JNJ-63723283) is a fully human immunoglobulin G4 (IgG4) kappa monoclonal antibody (mAb) that binds programmed-cell death protein (PD)-1. The mainstay of treatment for HR-NMIBC is transurethral resection of bladder tumor, followed by intravesical treatment with BCG. In this study metronomic dosing of intravesical gemcitabine, delivered via TAR-200, alone or in combination with cetrelimab will be evaluated and compared against intravesical BCG. The study consists of a Screening phase, Treatment phase, and Follow-up phase. The total duration of the study will be up to 5 years and 2 months. Efficacy, Safety, pharmacokinetics (PK), and biomarkers will be assessed at specific time points during the study.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 3
Udvidet adgang
Udvidet adgang
Godkendt
- Tilgængelig: Udvidet adgang er i øjeblikket tilgængelig for denne forsøgsbehandling, og patienter, der ikke er deltagere i den kliniske undersøgelse, kan muligvis få adgang til lægemidlet, det biologiske eller medicinske udstyr undersøgt.
- Ikke længere tilgængelig: Udvidet adgang var tilgængelig for denne intervention tidligere, men er ikke tilgængelig i øjeblikket og vil ikke være tilgængelig i fremtiden.
- Midlertidigt ikke tilgængelig: Udvidet adgang er i øjeblikket ikke tilgængelig for denne intervention, men forventes at være tilgængelig i fremtiden.
- Godkendt til markedsføring: Interventionen er blevet godkendt af U.S. Food and Drug Administration til brug for offentligheden.
Kontakter og lokationer
Studiesteder
-
-
-
Buenos Aires, Argentina, C1199
- Hospital Italiano de Buenos Aires
-
Buenos Aires, Argentina, C1417
- Sociedade Beneficente de Senhoras Hospital Sirio Libanes
-
Córdoba, Argentina, X5016KEH
- Hospital Privado Centro Medico de Cordoba
-
Córdoba, Argentina, 5000
- Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
-
Córdoba, Argentina, X5000KPH
- Centro Urologico Profesor Bengio
-
Mar del Plata, Argentina, B7602CBM
- Hospital Privado de la Comunidad
-
Río Cuarto, Argentina, 5800
- Instituto Medico Rio Cuarto
-
-
-
-
-
Heidelberg, Australien, 3084
- Austin Health
-
Macquarie University, Australien, 2109
- Macquarie University Hospital
-
Nedlands, Australien, 6009
- Hollywood Private Hospital
-
South Brisbane, Australien, 4101
- Mater Hospital Brisbane
-
-
-
-
-
Antwerp, Belgien, 2020
- ZNA Middelheim
-
Bruges, Belgien, 8000
- AZ Sint-Jan
-
Bruges, Belgien, 8310
- AZ Sint-Lucas
-
Ghent, Belgien, 9000
- AZ Maria Middelares
-
Ghent, Belgien, 9000
- UZ Gent
-
Libramont-Chevigny, Belgien, 6800
- Centre Hospitalier de l'Ardenne
-
Roeselare, Belgien, 8800
- AZ Delta
-
Sint-Niklaas, Belgien, 9100
- Vitaz
-
Wilrijk, Belgien, 2610
- GZA Ziekenhuizen- Campus St Augustinus
-
-
-
-
-
Barretos, Brasilien, 14784-400
- Fundacao Pio XII
-
Bauru, Brasilien, 17033-495
- NAIC Nair Antunes Instituto do Cancer
-
Campinas, Brasilien, 13083-888
- Hospital das Clinicas da Universidade Estadual de Campinas UNICAMP
-
Curitiba, Brasilien, 81520-060
- Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer
-
Natal, Brasilien, 59075-740
- Liga Norte Riograndense Contra O Cancer
-
Porto Alegre, Brasilien, 90050-170
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
Presidente Prudente, Brasilien, 19013-050
- Hospital Regional do Cancer Hospital de Esperanca
-
Salvador, Brasilien, 41253-190
- IDOR - Regional Bahia
-
Santa Cruz do Sul, Brasilien, 96835-090
- Hospital Ana Nery Santa Cruz do Sul
-
Santo André, Brasilien, 09060-870
- CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
-
São Paulo, Brasilien, 01509 900
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo, Brasilien, 01246 000
- Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
-
São Paulo, Brasilien, 05652 900
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo, Brasilien, 1321 001
- Real e Benemerita Associacao Portuguesa de Beneficencia
-
-
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- Nova Scotia Health Authority
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 4A6
- St Josephs Healthcare Hamilton
-
Toronto, Ontario, Canada, M5G 1Z5
- Princess Margaret Cancer Centre University Health Network
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 3E4
- CHUM - Centre hospitalier universitaire de Montreal
-
Québec, Quebec, Canada, G1J1Z4
- CHU de Quebec Universite Laval Hopital de l Enfant Jesus
-
Saint Jerome Quebec, Quebec, Canada, J7Z 2V4
- Unite de Recherche Clinique du CISSS des Laurentides
-
-
-
-
-
Edinburgh, Det Forenede Kongerige, EH4 2XU
- Western General Hospital
-
London, Det Forenede Kongerige, W6 8RF
- Charing Cross Hospital
-
London, Det Forenede Kongerige, SW3 6JJ
- The Royal Marsden NHS Trust
-
London, Det Forenede Kongerige, EC1A 7BE
- St Bartholomews Hospital
-
Plymouth, Det Forenede Kongerige, PL6 8DH
- Derriford Hospital
-
Scunthorpe, Det Forenede Kongerige, DN15 7BH
- Scunthorpe General Hospital
-
Sheffield, Det Forenede Kongerige, S10 2JF
- Sheffield Teaching Hospitals NHS Foundation Trust
-
Stevenage, Det Forenede Kongerige, SG1 4AB
- Lister Hospital
-
Truro, Det Forenede Kongerige, TR1 3LJ
- Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital
-
-
-
-
Arizona
-
Scottsdale, Arizona, Forenede Stater, 85259
- Mayo Clinic
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72211
- Arkansas Urology
-
-
California
-
Long Beach, California, Forenede Stater, 90822
- VA Long Beach Health Care System
-
Los Alamitos, California, Forenede Stater, 90720
- Genesis Research, LLC - West Coast Urology
-
Los Angeles, California, Forenede Stater, 90048
- Cedars Sinai Medical Center
-
Sacramento, California, Forenede Stater, 95630
- UC Davis Comprehensive Cancer Center
-
San Diego, California, Forenede Stater, 92123
- Genesis Research
-
Santa Monica, California, Forenede Stater, 90404
- Providence Saint Johns Cancer Institute
-
Santa Rosa, California, Forenede Stater, 95403
- Providence Medical Foundation
-
-
Colorado
-
Lakewood, Colorado, Forenede Stater, 80228
- Colorado Clinical Research
-
-
Florida
-
Hialeah, Florida, Forenede Stater, 33016
- Urological Research Network
-
Orlando, Florida, Forenede Stater, 32806
- Orlando Health Cancer Institute
-
Sarasota, Florida, Forenede Stater, 34239
- Sarasota Memorial Hospital
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30303
- Grady Memorial Hospital
-
Atlanta, Georgia, Forenede Stater, 30322
- The Emory Clinic Department of Urology
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Northwestern University
-
Lisle, Illinois, Forenede Stater, 60532
- Duly Health and Care
-
Quincy, Illinois, Forenede Stater, 62301
- Blessing Hospital
-
-
Indiana
-
Carmel, Indiana, Forenede Stater, 46032
- Urology of Indiana
-
Jeffersonville, Indiana, Forenede Stater, 47130
- First Urology
-
-
Kansas
-
Merriam, Kansas, Forenede Stater, 66204
- AMR Kansas City Oncology
-
Wichita, Kansas, Forenede Stater, 67226
- Wichita Urology Group
-
-
Maryland
-
Hanover, Maryland, Forenede Stater, 21076
- Chesapeake Urology Research Associates
-
-
Massachusetts
-
Burlington, Massachusetts, Forenede Stater, 01805
- Lahey Hospital & Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- University of Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55455
- University Of Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905
- Mayo Clinic Rochester
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68114
- The Urology Center, PC
-
-
New Jersey
-
Camden, New Jersey, Forenede Stater, 08103
- Cooper Health System MD Anderson Cancer Center at Cooper
-
-
New York
-
New York, New York, Forenede Stater, 10029
- Icahn School of Medicine at Mt. Sinai
-
New York, New York, Forenede Stater, 10010
- VA NY Harbor Healthcare System
-
Syracuse, New York, Forenede Stater, 13210
- SUNY Upstate Med Univ
-
Syracuse, New York, Forenede Stater, 13210
- Associated Medical Professionals of Ny
-
-
North Carolina
-
Greenville, North Carolina, Forenede Stater, 27834
- Vidant Urology - Greenville
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44195
- Cleveland Clinic
-
Gahanna, Ohio, Forenede Stater, 43230
- Central Ohio Urology Group
-
-
Pennsylvania
-
Bala-Cynwyd, Pennsylvania, Forenede Stater, 19004
- Centers for Advanced Urology LLC d b a MidLantic Urology
-
Philadelphia, Pennsylvania, Forenede Stater, 19107
- Thomas Jefferson University Hospital
-
Pittsburgh, Pennsylvania, Forenede Stater, 15232
- UPMC Shadyside Hospital
-
-
South Carolina
-
Myrtle Beach, South Carolina, Forenede Stater, 29572
- Carolina Urologic Research Center
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37232
- Vanderbilt University Medical Center
-
Nashville, Tennessee, Forenede Stater, 37209
- Urology Associates
-
-
Texas
-
Austin, Texas, Forenede Stater, 78745
- Urology Austin
-
Dallas, Texas, Forenede Stater, 75231
- Urology Clinics of North Texas
-
Houston, Texas, Forenede Stater, 77030
- Houston Methodist Hospital
-
Houston, Texas, Forenede Stater, 77027
- Houston Metro Urology
-
San Antonio, Texas, Forenede Stater, 78229
- Urology San Antonio Research
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84112
- Huntsman Cancer Institute
-
Salt Lake City, Utah, Forenede Stater, 84148
- George E. Wahlen VAMC
-
-
Virginia
-
Virginia Beach, Virginia, Forenede Stater, 23462
- Urology Of Virginia, Pllc
-
-
Washington
-
Spokane, Washington, Forenede Stater, 99202
- Spokane Urology
-
-
-
-
-
Bordeaux, Frankrig, 33000
- Polyclinique Bordeaux Nord Acquitaine
-
Clermont-Ferrand, Frankrig, 63003
- CHU Gabriel-Montpied
-
Grenoble, Frankrig, 38043
- CHU Grenoble
-
Limoges, Frankrig, 87000
- Polyclinique de Limoges - Francois Chenieux
-
Lyon, Frankrig, 69437
- Hôpital Edouard Herriot
-
Nantes, Frankrig, 44093
- CHU de Nantes hotel Dieu
-
Nîmes, Frankrig, 30029
- CHU Nimes
-
Orléans, Frankrig, 45067
- Centre Hospitalier Regional d'Orleans (CHRO) - Hopital La Source
-
Paris, Frankrig, 75013
- Hôpital Universitaire Pitié-Salpêtrière
-
Paris, Frankrig, 75018
- APHP - Hopital Bichat - Claude Bernard
-
Paris, Frankrig, 75960
- Groupe Hospitalier Diaconesses Croix Saint Simon
-
Paris, Frankrig, 75015
- Hopital Europeen Georges-Pompidou
-
Quint-Fonsegrives, Frankrig, 31130
- Clinical La Croix Du Sud - Ramsay Santé
-
Rennes, Frankrig, 35000
- Chu Rennes Hopital Pontchaillou
-
Strasbourg, Frankrig, 67200
- Institut de Cancerologie Strasbourg Europe ICANS
-
Toulouse, Frankrig, 31059
- CHU Rangueil
-
-
-
-
-
Hoofddorp, Holland, 2134 TM
- Spaarne Gasthuis
-
Nijmegen, Holland, 6524 KD
- Canisius-Wilhelmina Ziekenhuis
-
Nijmegen, Holland, 6525 GA
- Radboud Umcn
-
-
-
-
-
Bangalore, Indien, 560027
- Health Care Global Enterprises pvt Ltd
-
Chandigarh, Indien, 160012
- Post Graduate Institute of Medical Education And Research PGIMER
-
Gurugram, Indien, 122001
- Artemis Hospital
-
Kolkata, Indien, 700094
- Netaji Subhas chandra Bose Cancer Research Institute
-
Mumbai, Indien, 400012
- Tata Memorial Hospital
-
Pune, Indien, 411040
- CIMET s Inamdar Multispeciality Hospital
-
-
-
-
-
Acquaviva delle Fonti, Italien, 70021
- Generale Regionale F. Miulli
-
Asti, Italien, 14100
- Ospedale Cardinal Massaia
-
Avellino, Italien, 83100
- Ospedale San Giuseppe Moscati di Avellino
-
Castelfranco Veneto, Italien, 31033
- Ospedale San Giacomo Apostolo, Guardia pediatrica territoriale
-
Milan, Italien, 20141
- Istituto Europeo di Oncologia
-
Milan, Italien, 20132
- Ospedale San Raffaele di Milano
-
Naples, Italien, 80138
- Fondazione G Pascale Istituto Nazionale Tumori IRCCS
-
Ravenna, Italien, 48121
- Ospedale S. Maria Delle Croci
-
Rome, Italien, 00128
- Istituto Nazionale Tumori Regina Elena
-
-
-
-
-
Fuji-shi, Japan, 417-8567
- Fuji City General Hospital
-
Kanazawa, Japan, 920 8641
- Kanazawa University Hospital
-
Kashihara-shi, Japan, 634-8522
- Nara Medical University Hospital
-
Kisarazu-shi, Japan, 292-8535
- Kimitsu Chuo Hospital
-
Kobe, Japan, 650 0047
- Kobe City Medical Center General Hospital
-
Kumamoto, Japan, 860-0008
- National Hospital Organization Kumamoto Medical Center
-
Nagano, Japan, 381-8551
- Nagano Municipal Hospital
-
Nagasaki, Japan, 852-8501
- Nagasaki University Hospital
-
Nagasaki, Japan, 852-8511
- JRC Nagasaki Genbaku Hospital
-
Narashino-shi, Japan, 275-8580
- Saiseikai Narashino Hospital
-
Toon-shi, Japan, 791-0295
- Ehime University Hospital
-
Toyama, Japan, 930 0194
- Toyama University Hospital
-
Ube, Japan, 755-8505
- Yamaguchi University Hospital
-
Yokohama, Japan, 232 0024
- Yokohama City University Medical Center
-
-
-
-
-
Beijing, Kina, 100730
- Beijing Hospital
-
Beijing, Kina, 100034
- Peking University First Hospital
-
Beijing, Kina, 101100
- Beijing Luhe Hospital, Capital Medical University
-
Changchun, Kina, 130499
- The First Bethune Hospital of Jilin University
-
Changsha, Kina, 410013
- Hunan Province Cancer Hospital
-
Chengdu, Kina, 610044
- West China Hospital Sichuan University
-
Chongqing, Kina, 400000
- Chongqing University Cancer Hospital
-
Deyang, Kina, 618000
- People's Hospital of Deyang City
-
Guangzhou, Kina, 430030
- Sun Yat Sen University Cancer Center
-
Hangzhou, Kina, 310000
- Zhejiang Provincial People's Hospital
-
Hangzhou, Kina, 310016
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
-
Nanjing, Kina, 210008
- Nanjing Drum Tower Hospital
-
Ningbo, Kina, 315010
- The First Affiliated Hospital of Ningbo University
-
Shanghai, Kina, 200025
- Ruijing Hospital Affiliated To Shanghai Jiaotong University School Of Medicine
-
Shanghai, Kina, 200400
- Huadong Hospital Affiliated to Fudan University
-
Shenyang, Kina, 110004
- Shengjing Hospital Of China Medical University
-
Tianjin, Kina, 300211
- The Second Hospital Of Tianjin Medical University
-
Wenzhou, Kina, 325000
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan, Kina, 430030
- TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology
-
Xi'an, Kina, 710061
- First Affiliated Hospital of Medical College of Xi'an Jiaotong University
-
Yantai, Kina, 264000
- Yantai Yuhuangding Hospital
-
Zhengzhou, Kina, 450008
- Henan Cancer Hospital
-
-
-
-
-
Mexico City, Mexico, 14308
- Consultorio Medico dentro del Hospital Angeles Acoxpa
-
Monterrey, Mexico, 64460
- Hospital Universitario Dr Jose Eleuterio Gonzalez
-
Monterrey, Mexico, 64710
- Avix Investigacion Clinica S C
-
Mérida, Mexico, 97000
- Eme Red Hospitalaria
-
San Luis Potosí City, Mexico, 78260
- Oncologico Potosino
-
-
-
-
-
Bialystok, Polen, 15 276
- Uniwersytecki Szpital Kliniczny w Bialymstoku
-
Bydgoszcz, Polen, 85 048
- IN VIVO Sp. z o.o
-
Lublin, Polen, 20 708
- Wojewodzki Szpital Specjalistyczny im Stefana Kardynala Wyszynskiego SPZOZ
-
Piotrkow Trybunalski, Polen, 97 300
- Centrum Medyczne
-
Poznan, Polen, 61 731
- Clinical Research Center sp z o o MEDIC R s k
-
Słupsk, Polen, 76-200
- Wojewodzki Szpital Specjalistyczny im Janusza Korczaka
-
Warsaw, Polen, 02-781
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
-
Warsaw, Polen, 02-647
- Provita Poliklinika
-
Wroclaw, Polen, 50 556
- Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu
-
-
-
-
-
Coimbra, Portugal, 3000-075
- Ipo Coimbra
-
Lisbon, Portugal, 1769 001
- Uls Santa Maria - Hosp. Santa Maria
-
Vila Nova de Gaia, Portugal, 4434 502
- Uls Gaia Espinho
-
-
-
-
-
A Coruña, Spanien, 15006
- Hosp Univ A Coruna
-
Algeciras, Spanien, 11207
- Hosp. Punta de Europa
-
Barcelona, Spanien, 08025
- Fund. Puigvert
-
Cadiz, Spanien, 11009
- Hosp. Puerta Del Mar
-
Castellon, Spanien, 12004
- Hosp. Gral. Univ. de Castellon
-
L'Hospitalet de Llobregat, Spanien, 08907
- Hosp. Univ. de Bellvitge
-
Lugo, Spanien, 27003
- Hosp. Univ. Lucus Augusti
-
Madrid, Spanien, 28041
- Hosp. Univ. 12 de Octubre
-
Madrid, Spanien, 28046
- Hosp. Univ. La Paz
-
Madrid, Spanien, 28027
- Clinica Univ. de Navarra
-
Málaga, Spanien, 29010
- Hosp Virgen de La Victoria
-
Santander, Spanien, 39008
- Hosp. Univ. Marques de Valdecilla
-
Valencia, Spanien, 46010
- Hosp. Clinico Univ. de Valencia
-
-
-
-
-
Busan, Sydkorea, 49241
- Pusan National University Hospital
-
Cheongju-si, Sydkorea, 28644
- Chungbuk National University Hospital
-
Daegu, Sydkorea, 41404
- Kyungpook National University Chilgok Hospital
-
Daegu, Sydkorea, 42601
- Keimyung University Dongsan Hospital
-
Gyeonggi-do, Sydkorea, 10408
- National Cancer Center
-
Jeollanam-do, Sydkorea, 58128
- Chonnam National University Hwasun Hospital
-
Seoul, Sydkorea, 03080
- Seoul National University Hospital
-
Seoul, Sydkorea, 03722
- Severance Hospital Yonsei University Health System
-
Seoul, Sydkorea, 06351
- Samsung Medical Center
-
Seoul, Sydkorea, 03181
- Kangbuk Samsung Hospital
-
Seoul, Sydkorea, 06591
- The Catholic University of Korea Seoul St Marys Hospital
-
Seoul, Sydkorea, 02841
- Korea University Anam Hospital
-
-
-
-
-
Kaohsiung City, Taiwan, 833
- Chang Kung Memorial Hospital
-
Kaohsiung City, Taiwan, 807
- Kaohsiung Medical University Chung Ho Memorial Hospital
-
Taichung, Taiwan, 404
- China Medical University Hospital
-
Taichung, Taiwan, 40705
- Taichung Veterans General Hospital
-
Taipei, Taiwan, 11217
- Taipei Veterans General Hospital
-
Taoyuan, Taiwan, 33382
- Linkou Chang Gung Memorial Hospital
-
-
-
-
-
Brno, Tjekkiet, 65691
- Fakultni nemocnice u sv. Anny v Brne
-
Hradec Králové, Tjekkiet, 500 05
- Fakultni nemocnice Hradec Kralove
-
Liberec, Tjekkiet, 460 01
- Krajská nemocnice Liberec a.s.
-
Olomouc, Tjekkiet, 779 00
- Fakultni nemocnice Olomouc
-
Prague, Tjekkiet, 100 34
- Fakultni nemocnice Kralovske Vinohrady
-
Prague, Tjekkiet, 15006
- Fakultni nemocnice v Motole
-
Prague, Tjekkiet, 140 59
- Thomayerova nemocnice, Onkologicka klinika
-
-
-
-
-
Cologne, Tyskland, 50968
- Urologische Partnerschaft Koln UPK
-
Duisburg, Tyskland, 47169
- Urologicum Duisburg
-
Erlangen, Tyskland, 91054
- Universitatsklinikum Erlangen
-
Essen, Tyskland, 45147
- Universitatsklinikum Essen
-
Frankfurt am Main, Tyskland, 60590
- Universitaetsklinikum Frankfurt
-
Freiburg im Breisgau, Tyskland, 79106
- Universitaetsklinikum Freiburg
-
Markkleeberg, Tyskland, 04416
- Matthias Schulze - Germany
-
Mettmann, Tyskland, 40822
- Urologie Neandertal Praxis Mettmann
-
München, Tyskland, 81675
- Klinikum rechts der Isar an der Technischen Universitat Munchen
-
Münster, Tyskland, 48149
- Universitatsklinikum Munster
-
Nuremberg, Tyskland, 90491
- Medizinisches Versorgungszentrum - Urologie
-
Nuremberg, Tyskland, 90419
- Klinikum Nurnberg Nord
-
Nürtingen, Tyskland, 72622
- Studienpraxis Urologie Nurtingen
-
Regensburg, Tyskland, 93053
- Caritas-Krankenhaus St. Josef
-
Tübingen, Tyskland, 72076
- Universitat Tubingen
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Histologically confirmed initial diagnosis by local pathology (within 90 days of the most recent signed informed consent) of high grade non-muscle invasive bladder cancer (HR-NMIBC) (high-grade Ta, any T1 or carcinoma in-situ [CIS]), in participants who are Bacillus Calmette Guérin (BCG)-naïve
- BCG-naïve (participants who have not received prior intravesical BCG or who previously received but stopped BCG more than 3 years before date of randomization are eligible)
- All visible papillary disease must be fully resected (absent) prior to date of randomization and documented at baseline cystoscopy. Local urine cytology at screening must be negative or atypical (for high-grade urothelial carcinoma [HGUC]) for patients with papillary only disease (without CIS)
- Eastern Cooperative Oncology Group (ECOG) performance status Grade 0, 1, or 2
- All adverse events associated with any prior surgery and/or intravesical therapy must have resolved to common terminology criteria for adverse events (CTCAE) version 5.0 Grade less than (<) 2 prior to date of randomization
- Participants must be willing to undergo all study procedures
Exclusion Criteria:
- Presence or history of histologically confirmed, muscle invasive, locally advanced, nonresectable, or metastatic urothelial carcinoma (that is, greater than and equal to [>=] T2)
- Must not have had urothelial carcinoma or histological variant at any site outside of the urinary bladder (that is, urethra, ureter, or renal pelvis). Ta/any T1/CIS of the upper urinary tract (including renal pelvis and ureter) is allowable if treated with complete nephroureterectomy more than 24 months prior to randomization
- Presence of any bladder or urethral anatomic feature (example, urethral stricture) that, in the opinion of the investigator, may prevent the safe insertion, indwelling use, removal of TAR-200 or administration of intravesical BCG. Participants with tumors involving the prostatic urethra in men will be excluded
- A history of clinically significant polyuria with recorded 24-hour urine volumes greater than 4000 milliliters (mL)
- Indwelling catheters are not permitted; however, intermittent catheterization is acceptable
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Treatment Group A: TAR-200 + Cetrelimab
Participants will receive intravesical TAR-200 once every 3 weeks (Q3W) and cetrelimab. |
Cetrelimab will be administered.
Andre navne:
TAR-200 will be administered intravesically.
Andre navne:
|
|
Aktiv komparator: Treatment Group B: Bacillus Calmette-Guerin (BCG) Vesiculture
Participants will receive intravesical BCG once every week for 6 weeks (induction) and then followed by once every week for 3 weeks starting at Weeks 12, 24, 48, 72, and 96 (maintenance). |
BCG will be administered intravesically. |
|
Eksperimentel: Treatment Group C: TAR-200 Alone
Participants will receive intravesical TAR-200 alone once Q3W. |
TAR-200 will be administered intravesically.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Event-free Survival (EFS)
Tidsramme: Up to 5 years 2 months
|
EFS is defined as the time from randomization to either the time of the first recurrence of high-risk disease, progression, or death due to any cause, whichever occurs first. For participants with carcinoma In-situ (CIS), persistent disease at 6 months (Week 24) is also considered an EFS event. Progression is defined as: an increase of stage from Ta to T1 or from CIS to T1 or progression to muscle invasive bladder cancer (MIBC) (T greater than or equal to [>=] 2) or to lymph node (N+) or to distant disease (M+), whichever occurs first. |
Up to 5 years 2 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Complete Response (CR) Rate
Tidsramme: Up to 5 years 2 months
|
Overall CR will be measured by determining the percentage of participants with CIS who have no presence of high-risk disease at 6 months. |
Up to 5 years 2 months
|
|
Duration of CR
Tidsramme: Up to 5 years 2 months
|
Duration of CR is defined from the time of first CR achieved to first evidence of recurrence, progression or death due to any cause (whichever occurs first) for participants who achieve a CR. |
Up to 5 years 2 months
|
|
Recurrence-Free Survival (RFS)
Tidsramme: Up to 5 years 2 months
|
RFS is defined as the time from randomization to the time of the first recurrence of high-risk disease, or death due to any cause, whichever occurs first. |
Up to 5 years 2 months
|
|
Time to Progression (TTP)
Tidsramme: Up to 5 years 2 months
|
TTP is defined as the time from randomization to the date of first documented evidence of disease progression or death due to disease progression, whichever occurs first. |
Up to 5 years 2 months
|
|
Overall Survival (OS)
Tidsramme: Up to 5 years 2 months
|
OS is defined as the time from randomization to death, due to any cause. |
Up to 5 years 2 months
|
|
Cancer Specific Survival (CSS)
Tidsramme: Up to 5 years 2 months
|
CSS is defined as the time from randomization to the date of death due to bladder cancer. |
Up to 5 years 2 months
|
|
Number of Participants with Adverse Events (AEs) by Grades According to Common Terminology Criteria for Adverse Events (CTCAE)
Tidsramme: Up to 5 years 2 months
|
Number of participants with AEs by severity grade as assessed by CTCAE version 5 will be reported. Grade refers to the severity of AE as follows: Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening; Grade 5- Death related to adverse event. |
Up to 5 years 2 months
|
|
Number of Participants with Adverse Events (AEs)
Tidsramme: Up to 5 years 2 months
|
Number of participants with AEs will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. |
Up to 5 years 2 months
|
|
Number of Participants with Change from Baseline in Laboratory Abnormalities
Tidsramme: Up to 5 years 2 months
|
Number of participants with change from baseline in laboratory abnormalities will be reported. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1- Mild, Grade 2- Moderate, Grade 3- Severe, Grade 4- Life-threatening, and Grade 5- Death related to adverse event. |
Up to 5 years 2 months
|
|
Number of Participants with Change from Baseline in Vital Signs Abnormalities
Tidsramme: Up to 5 years 2 months
|
Number of participants with change from baseline in vital signs (blood pressure [systolic and diastolic], heart rate, temperature, and weight) abnormalities will be reported. |
Up to 5 years 2 months
|
|
Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of life Questionnaire - Non-muscle Invasive Bladder Cancer EORTC QLQ- NMIBC 24
Tidsramme: Up to 5 years 2 months
|
EORTC QLQ-NMIBC 24 is a 24-item questionnaire for evaluating the Health-related quality of life (HRQoL) of participants with superficial (non-muscle-invasive) bladder cancer. The questionnaire is designed to supplement the quality of life questionnaire (QLQ-C30) and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). |
Up to 5 years 2 months
|
|
Time to Symptom Deterioration as Assessed by EORTC-QLQ-NMIBC 24 Scores
Tidsramme: Up to 5 years 2 months
|
EORTC QLQ-NMIBC 24 is a 24-item questionnaire for evaluating the HRQoL of participants with superficial (non-muscle-invasive) bladder cancer. The questionnaire is designed to supplement the QLQ-C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). |
Up to 5 years 2 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CR109223
- 2020-004506-64 (EudraCT nummer)
- 17000139BLC3002 (Anden identifikator: Janssen Research & Development, LLC)
- 2023-507187-39-00 (Registry Identifier: EUCT number)
- 2023 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .